Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 11 - 18 |
| Updated: | 12/2/2016 |
| Start Date: | February 2006 |
| End Date: | April 2007 |
A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B
meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11
to 18 years.
meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11
to 18 years.
Inclusion Criteria:
- Healthy Adolescents between and including 11-18 years of age, who provide written
informed consent.
Exclusion Criteria:
- Previous or suspected disease caused by N. meningitidis; or previous immunization
with a serogroup B meningococcal vaccine; Any acute, chronic or progressive disease.
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials